# US 2022/0033764 A1 · Engineered microorganisms and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033764 A1
- Document ID: US20220033764A1
- Status: Published application
- Kind: A1
- Application number: 17/278,027
- Filed: 2019-09-20
- Published: 2022-02-03
- Earliest claimed: 2018-09-20
- Assignees: Vir Biotechnology, Inc.
- Applicants: Washington University; Vir Biotechnology, Inc.
- Inventors: Gautam DANTAS; Suryang KWAK; Herbert VIRGIN
- Web page: https://patentgrep.com/patent/US20220033764A1

## CPC

- C12N 1/20: Bacteria; Culture media therefor
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- A61K 36/064: Saccharomycetales, e.g. baker's yeast
- C07K 14/395: from Saccharomyces
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G01N 33/56911: {Bacteria}
- G01N 33/56983: {Viruses}
- C12R 2001/865: Saccharomyces cerevisiae
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides for engineered microorganisms and methods of making and using same. The engineered microorganisms as described herein can have a surface display and can be useful as therapeutic agents (e.g., sponges) and biosensors.

## Claims

### Claim 1

An engineered microorganism comprising:
at least one binding agent displayed on a surface of the engineered microorganism, wherein the binding agent has a binding affinity to a target microorganism.

### Claim 2 (depends on 1)

The engineered microorganism of claim 1, wherein the binding agent is operably linked to the engineered microorganism via an anchor protein.

### Claim 3 (depends on 2)

The engineered microorganism of claim 2, wherein the anchor protein is a cell wall protein anchor region.

### Claim 4 (depends on 3)

The engineered microorganism of claim 3, wherein the cell wall protein anchor region is a Flo1p anchor region.

### Claim 5 (depends on 1)

The engineered microorganism of claim 1, wherein the binding agent is operably linked to the engineered microorganism via a stem comprising a transmembrane protein.

### Claim 6 (depends on 5)

The engineered microorganism of claim 5, wherein the transmembrane protein is selected from Wsc1p (C8A).

### Claim 7 (depends on 5)

The engineered microorganism of claim 5, wherein the stem comprises a cell wall protein domain operably linked to the transmembrane protein, wherein the cell wall protein domain is capable of extending the stem into extracellular space.

### Claim 8 (depends on 7)

The engineered microorganism of claim 7, wherein the cell wall protein domain is Mid2 protein (Mid2p).

### Claim 9 (depends on 1)

The engineered microorganism of claim 1, comprising a first binding agent and a second binding agent, wherein the first binding agent is capable of binding to a first target microorganism and the second binding agent is capable of binding to a second target microorganism and the first binding agent is different from the second binding agent.

### Claim 10 (depends on 1)

The engineered microorganism of claim 1, wherein the engineered microorganism is Saccharomyces yeast.

### Claim 11 (depends on 10)

The engineered microorganism of claim 10, wherein the engineered microorganism is selected from Saccharomyces cerevisiae var. boulardii (S. boulardii).

### Claim 12 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is a pathobiont, a commensal microorganism, or a pathogen.

### Claim 13 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is a bacteria, a fungi, a virus, or a eukaryote.

### Claim 14 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is selected from the group consisting of Norovirus, Listeria monocytogenes, Clostridium pathobionts, Clostridium difficile, Clostridium perfringens, Campylobacter coli, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Salmonella, P. aeruginosa, E. coli, and any other biological entity having a binding region that can be targeted by a binding agent, such as scFvs, receptors, or binding domains.

### Claim 15 (depends on 1)

The engineered microorganism of claim 1, wherein the binding agent specifically binds to the target microorganism.

### Claim 16 (depends on 1)

The engineered microorganism of claim 1, wherein the binding agent comprises one or more of the group consisting of: peptides, proteins, antibodies, nanobodies, single chain fragments thereof, and combinations thereof.

### Claim 17 (depends on 1)

The engineered microorganism of claim 1, wherein the binding agent comprises one or more of the group consisting of: a cell wall binding domain of a target microorganism and a cell wall binding domain of an endolysin.

### Claim 18 (depends on 2)

The engineered microorganism of claim 2, wherein the anchor protein comprises a cell wall protein anchor region in a single cistron bracketed by a promoter and a terminator.

### Claim 19 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is norovirus and the binding agent is CLM-1.

### Claim 20 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is Clostridium pathobionts (C. difficile/perfringens) and the binding agent is cell binding domain of ϕCP26F (PlyCP26F).

### Claim 21 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is Listeria monocytogenes and the binding agent is cell binding domain 500 of endolysin Ply500 or cell wall binding domain of PlyP35.

### Claim 22 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is Streptococcus pyogenes and the binding agent is PlyC binding domain of endolysin PlyC.

### Claim 23 (depends on 1)

The engineered microorganism of claim 1, wherein the target microorganism is methicillin-resistant Staphylococcus aureus (MRSA) or Staphylococcus aureus and the binding agent is LysGH15B, a cell wall binding domain of endolysin LysGH15, LysSA97, or ZW88.

### Claim 24 (depends on 1)

The engineered microorganism of claim 1, the target microorganism is Campylobacter coli and the binding agent is a cell wall binding domain of phiCcolBB35.

### Claim 25 (depends on 1)

The engineered microorganism of claim 1, further comprising a transactivator operably linked to a transmembrane protein via a conditionally cleavable peptide.

### Claim 26 (depends on 25)

The engineered microorganism of claim 25, wherein the conditionally cleavable peptide is cleavable when in the presence of ubiquitinase.

### Claim 27 (depends on 25)

The engineered microorganism of claim 25, wherein the transactivator comprises an RNA-guided DNA endonuclease enzyme.

### Claim 28 (depends on 27)

The engineered microorganism of claim 27, wherein the RNA-guided DNA endonuclease enzyme is nuclease-null Cas9 (dCas9).

### Claim 29 (depends on 27)

The engineered microorganism of claim 27, wherein the RNA-guided DNA endonuclease enzyme corresponds to a display unit integrated into an intergenic site.

### Claim 30 (depends on 29)

The engineered microorganism of claim 29, wherein the engineered microorganism is S. boulardii and the intergenic site is selected from Chr VII, XII, XV, XVI, or combinations thereof.

### Claim 31 (depends on 25)

The engineered microorganism of claim 25, wherein
a first split ubiquitin fragment is operably linked to transmembrane protein;
a transactivator is operably to the transmembrane protein via a second split ubiquitin fragment; and
physical interaction between the first split ubiquitin fragment and the second split ubiquitin fragment releases the transactivator.

### Claim 32 (depends on 31)

The engineered microorganism of claim 31, wherein
the first split ubiquitin fragment comprises a N-terminal 37 amino acid residues of ubiquitin is operably linked to transmembrane protein; and
the second split ubiquitin fragment comprises a C-terminal 42 amino acid residues of ubiquitin.

### Claim 33 (depends on 25)

The engineered microorganism of claim 25, wherein the transactivator comprises a scRNA-binding motif and a transcription activator capable of initiating expression of a reporter protein.

### Claim 34 (depends on 33)

The engineered microorganism of claim 33, wherein the reporter protein is selected from a fluorescent protein, such as GFP, RFP, BFP, or a luminescence protein, such as luciferase.

### Claim 35 (depends on 25)

The engineered microorganism of claim 25, wherein the transactivator comprises a transcriptional activation domain.

### Claim 36 (depends on 35)

The engineered microorganism of claim 35, wherein the transcriptional activation domain comprises VP64.

### Claim 37 (depends on 25)

The engineered microorganism of claim 25, wherein the transactivator comprises an RNA stem loop recognition domain and the RNA stem loop recognition domain is fused to an intracellular enzyme-cleavable-binding fragment.

### Claim 38 (depends on 37)

The engineered microorganism of claim 37, wherein the RNA stem loop recognition domain is selected from MCP, PCP, or Com.

### Claim 39 (depends on 37)

The engineered microorganism of claim 37, wherein the intracellular enzyme-cleavable-binding fragment is a ubiquitin fragment.

### Claim 40 (depends on 1)

The engineered microorganism of claim 1, wherein the engineered microorganism comprises a reporter gene.

### Claim 41 (depends on 40)

The engineered microorganism of claim 40, wherein the reporter gene is selected from GFP, RFP, BFP, luminescence proteins, or combinations thereof.

### Claim 42 (depends on 1)

The engineered microorganism of claim 1, wherein the engineered microorganism is selected from a microorganism that does not colonize in a mammalian gut.

### Claim 43 (depends on 1)

A method of targeted sensing, detecting, or killing of commensal or pathogenic gut microbes comprising administering a therapeutically effective amount of the engineered microorganism of claim 1.

### Claim 44 (depends on 1)

A method of treating a gut disease comprising administering a therapeutically effective amount of an engineered microorganism of claim 1.

### Claim 45 (depends on 1)

A method of regulating commensal gut microbiota comprising contacting a therapeutically effective amount of an engineered microorganism of claim 1.

### Claim 46

A method of constructing an engineered microorganism comprising:
providing a microorganism;
providing a display cassette; and
integrating the display cassette into an intergenic site of the microorganism genome;
wherein,
the display cassette comprises a sequence for expression of a binding agent; a promoter capable of expressing the binding agent; a terminator; an anchor; and a secretion signal peptide.

### Claim 47 (depends on 46)

The method of claim 46, wherein the anchor comprises a cell wall protein anchor region in a single cistron bracketed by a constitutive promoter and a terminator.

### Claim 48 (depends on 46)

The method of claim 46, wherein the anchor is selected from Cwp2p, Sed1p, Ccw12p, or Flo1p from Saccharomyces yeasts.

### Claim 49 (depends on 46)

The method of claim 46, wherein the anchor is selected from Flo1p.

### Claim 50

A method of constructing an engineered microorganism comprising:
providing a microorganism;
providing a display cassette; and
integrating the display cassette into an intergenic site of the microorganism genome;
wherein,
the display cassette comprises a sequence for expression of a binding agent; a constitutive promoter; a terminator; a stem comprising a transmembrane domain of a microorganism cell wall protein; a secretion signal peptide; and an intracellular enzyme-cleavable-binding fragment operably linked to a transactivator.

### Claim 51 (depends on 50)

The method of claim 50, wherein the transmembrane domain of a microorganism cell wall protein is selected from Wsc1p (C8A).

### Claim 52 (depends on 50)

The method of claim 50, wherein the display cassette further comprises a cell wall protein domain operably linked to the stem, wherein the cell wall protein domain is capable of extending the stem into extracellular space.

### Claim 53 (depends on 50)

The method of claim 50, comprising:
a first pair of binding agents and a second pair of binding agents; and
a first transactivator and a second transactivator; wherein
the first pair of binding agents are capable of binding to a first target microorganism and the second pair of binding agents are capable of binding to a second target microorganism and the first pair of binding agents are different from the second pair of binding agents;
the first pair of binding agents are operably linked to a first pair of intracellular enzyme-cleavable-binding fragment via a first transmembrane protein, wherein one of the first pair of the first intracellular enzyme-cleavable-binding fragment is operably linked to the first transactivator;
the second binding agent is operably linked to a second pair of intracellular enzyme-cleavable-binding fragment via a second transmembrane protein, wherein one of the second pair of the second intracellular enzyme-cleavable-binding fragment is operably linked to a second transactivator; and
one of the first pair of intracellular enzyme-cleavable-binding fragments and one of the second pair of intracellular enzyme-cleavable-binding fragments have the same binding protein in the N-terminal region, but have different transactivators in the C-terminal region, which are capable of physically interacting with target microorganisms, and releasing the first or the second transactivators.

### Claim 54 (depends on 46, 50)

The method of any one of claim 46 or 50, wherein the binding agent comprises one or more of the group consisting of: peptides, proteins, antibodies, nanobodies, single chain fragments thereof, and combinations thereof.

### Claim 55 (depends on 46, 50)

The method of any one of claim 46 or 50, wherein the binding agent comprises one or more of the group consisting of: a cell wall binding domain of a target microorganism and a cell wall binding domain of an endolysin.

### Claim 56 (depends on 46, 50)

The method of any one of claim 46, 50, or 53, wherein the binding agent is selected from CLM-1; ZW88; cell binding domain of (1)CP26F (PlyCP26F); cell binding domain 500 of endolysin Ply500; PlyC binding domain of endolysin PlyC; LysGH15B, a cell wall binding domain of endolysin LysGH15 or LysSA97; or cell wall binding domain of phiCcolBB35.

### Claim 57 (depends on 50)

The method of claim 50, wherein the transactivator is operably linked to a transmembrane protein via a conditionally cleavable peptide.

### Claim 58 (depends on 50)

The method of claim 50, wherein the transactivator comprises an RNA-guided DNA endonuclease enzyme.

### Claim 59 (depends on 58)

The method of claim 58, wherein the RNA-guided DNA endonuclease enzyme corresponds to a display unit integrated into an intergenic site.

### Claim 60 (depends on 50)

The method of claim 50, wherein a nuclease-null Cas9 (dCas9) and a scaffold RNA recruit the transactivator to corresponding synthetic promoters.

### Claim 61 (depends on 50)

The method of claim 50, wherein the transactivator comprises a scRNA-binding motif and a transactivator capable of initiating the expression of a reporter or biomolecule.

### Claim 62 (depends on 50)

The method of claim 50, wherein the transactivator comprises a transcriptional activation domain.

### Claim 63 (depends on 50)

The method of claim 50, wherein the transactivator comprises an RNA stem loop recognition domain fused to an intracellular enzyme-cleavable-binding fragment.

### Claim 64 (depends on 50)

The method of claim 50, comprising initiating transcription of target reporter proteins.

### Claim 65 (depends on 64)

The method of claim 64, wherein the target reporter proteins are selected from a fluorescent protein and a luminescence protein.

### Claim 66 (depends on 64)

The method of claim 64, wherein the target reporter proteins are selected from the group consisting of: GFP, RFP, BFP, luciferase, or combinations thereof.

### Claim 67 (depends on 46, 50)

The method of any one of claim 46 or 50, wherein the microorganism is selected from S. boulardii and the intergenic site is selected from Chr VII, XII, XV, or XVI, or a combination thereof; and corresponding guide RNAs for Cas9 yield stable expression of target proteins without interference in native transcriptions of the microorganism.

### Claim 68 (depends on 46, 50)

The method of any one of claim 46 or 50, wherein frameworks for stable expression of target proteins do not require an inducer.

### Claim 69 (depends on 46, 50)

The method of any one of claim 46 or 50, comprising a strong constitutive promoter or weak promoter of the engineered microorganism.

### Claim 70 (depends on 69)

The method of claim 69, wherein the strong constitutive promoter is selected from TDH3 or CCW12 promoters of S. boulardii.

### Claim 71 (depends on 69)

The method of claim 69, wherein the weak promoter is selected from WSC1 or FAU1 promoters of S. boulardii.

### Claim 72 (depends on 69)

The method of claim 69, further comprising a terminator.

### Claim 73 (depends on 72)

The method of claim 72, wherein the terminator is selected from ADH1 or CYC1 terminators of S. boulardii.
